Literature DB >> 16847564

Serum decreases the size of Metafectene-and Genejammer-DNA complexes but does not affect significantly their transfection activity in SCCVII murine squamous cell carcinoma cells.

Krystyna Konopka1, Nathan Overlid, Anitha C Nagaraj, Nejat Düzgüneş.   

Abstract

Cationic liposome-DNA (lipoplexes) or polymer-DNA (polyplexes) complexes have been used to deliver therapeutic genes, both in vitro and in vivo. However, gene transfer by these non-viral vectors is usually inhibited by biological milieu. A relatively high efficiency of transfection could be achieved in human oral cancer cells transfected with the polycationic liposome, Metafectene, and the polyamine reagent, GeneJammer, in the presence of 60% fetal bovine serum (FBS) (Konopka et al., Cell. Mol. Biol. Lett. 10 (2005) 455-470). Here, we examined the efficacy of these vectors to deliver beta-galactosidase (beta-gal), luciferase and Herpes Simplex Virus thymidine kinase (HSV-tk) genes to SCCVII murine squamous cell carcinoma cells, which are used to generate an orthotopic murine model of oral cancer. We also evaluated the hydrodynamic size and zeta potential of the vectors and the effect of FBS and mouse serum (up to 60%) on the size of Metafectene and GeneJammer complexes with the pCMV.Luc plasmid. Our results indicate that Metafectene and GeneJammer are highly effective in transfecting SCCVII cells. Approximately 60-70% of SCCVII cells transfected with pCMV.lacZ were positive for beta-gal staining. The expression of beta-galactosidase was essentially not affected by serum. Mouse serum (20-60%) reduced both Metafectene-and GeneJammer-mediated luciferase expression by approximately 30-45%, while FBS did not affect transfection efficiency. The delivery of the HSV-tk gene by Metafectene or GeneJammer in the presence of 0% or 60% FBS, followed by GCV treatment for 6 days, resulted in over 90% cytotoxicity. The mean diameters of the DNA complexes of Metafectene and GeneJammer decreased significantly as a function of the serum concentration. The reduction in the size of the lipoplexes and polyplexes by serum was essentially not inhibitory to transfection of SCCVII cells. This is in contrast to previous hypotheses that serum-induced decrease in the size of lipoplexes is the primary cause of serum inhibition of transfection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16847564      PMCID: PMC6276004          DOI: 10.2478/s11658-006-0015-5

Source DB:  PubMed          Journal:  Cell Mol Biol Lett        ISSN: 1425-8153            Impact factor:   5.787


  52 in total

1.  Tumor reduction in vivo after adenoviral mediated gene transfer of the herpes simplex virus thymidine kinase gene and ganciclovir treatment in human head and neck squamous cell carcinoma.

Authors:  E A Goebel; B L Davidson; S M Graham; J A Kern
Journal:  Otolaryngol Head Neck Surg       Date:  1998-10       Impact factor: 3.497

2.  The role of interleukin-2 in combination adenovirus gene therapy for head and neck cancer.

Authors:  B W O'Malley; D A Sewell; D Li; K Kosai; S H Chen; S L Woo; L Duan
Journal:  Mol Endocrinol       Date:  1997-06

3.  Serum-resistant gene transfer to oral cancer cells by Metafectene and GeneJammer: application to HSV-tk/ganciclovir-mediated cytotoxicity.

Authors:  Krystyna Konopka; Basma Fallah; JoMarie Monzon-Duller; Nathan Overlid; Nejat Düzgünes
Journal:  Cell Mol Biol Lett       Date:  2005       Impact factor: 5.787

4.  Lipid mixing between lipoplexes and plasma lipoproteins is a major barrier for intravenous transfection mediated by cationic lipids.

Authors:  Bouna-Moussa Tandia; Caroline Lonez; Michel Vandenbranden; Jean-Marie Ruysschaert; Abdelatif Elouahabi
Journal:  J Biol Chem       Date:  2005-01-20       Impact factor: 5.157

5.  Evaluation of polyplexes as gene transfer agents.

Authors:  C L Gebhart; A V Kabanov
Journal:  J Control Release       Date:  2001-06-15       Impact factor: 9.776

6.  Combination nonviral interleukin 2 and interleukin 12 gene therapy for head and neck squamous cell carcinoma.

Authors:  D Li; E Shugert; M Guo; J S Bishop; B W O'Malley
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2001-11

7.  Suicide gene therapy for human oral squamous cell carcinoma cell lines with adeno-associated virus vector.

Authors:  T Fukui; Y Hayashi; H Kagami; N Yamamoto; H Fukuhara; I Tohnai; M Ueda; M Mizuno; J Yoshida
Journal:  Oral Oncol       Date:  2001-04       Impact factor: 5.337

8.  Cellular and molecular barriers to gene transfer by a cationic lipid.

Authors:  J Zabner; A J Fasbender; T Moninger; K A Poellinger; M J Welsh
Journal:  J Biol Chem       Date:  1995-08-11       Impact factor: 5.157

9.  Patterns of relapse in locally advanced head and neck cancer patients who achieved complete remission after combined modality therapy.

Authors:  W K Hong; R H Bromer; D A Amato; S Shapshay; M Vincent; C Vaughan; B Willett; A Katz; J Welch; S Fofonoff
Journal:  Cancer       Date:  1985-09-15       Impact factor: 6.860

Review 10.  Gene therapy for the treatment of oral squamous cell carcinoma.

Authors:  S Xi; J R Grandis
Journal:  J Dent Res       Date:  2003-01       Impact factor: 6.116

View more
  4 in total

1.  Theranostic nanoemulsions for macrophage COX-2 inhibition in a murine inflammation model.

Authors:  Sravan Kumar Patel; Wissam Beaino; Carolyn J Anderson; Jelena M Janjic
Journal:  Clin Immunol       Date:  2015-05-08       Impact factor: 3.969

2.  Synthesis and evaluation of tetramethylguanidinium-polyethylenimine polymers as efficient gene delivery vectors.

Authors:  Manohar Mahato; Santosh Yadav; Pradeep Kumar; Ashwani Kumar Sharma
Journal:  Biomed Res Int       Date:  2014-04-24       Impact factor: 3.411

Review 3.  Nucleic acid targeting: towards personalized therapy for head and neck cancer.

Authors:  S M Parsel; J R Grandis; S M Thomas
Journal:  Oncogene       Date:  2015-11-23       Impact factor: 9.867

4.  Correlation between the levels of survivin and survivin promoter-driven gene expression in cancer and non-cancer cells.

Authors:  Krystyna Konopka; Christopher Spain; Allison Yen; Nathan Overlid; Senait Gebremedhin; Nejat Düzgüneş
Journal:  Cell Mol Biol Lett       Date:  2008-10-06       Impact factor: 5.787

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.